Home » Three Healthcare Titans Make Deals to Expand Their Portfolios

Three Healthcare Titans Make Deals to Expand Their Portfolios

December 4, 2023

Drugs Devices Commercial Operations Commercial Operations

Roche has announced the $2.7 billion acquisition of Carmot Therapeutics, including that company’s three potential incretin obesity and diabetes drugs.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00

21Oct
MAGI@home Clinical Research Conference 2024

Three Healthcare Titans Make Deals to Expand Their Portfolios

To View This Article:

Login

Buy This Article Now

Upcoming Events

MAGI@home Clinical Research Conference 2024

Featured Products

From QSR to QMSR: Meeting FDA’s New Requirements

FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule

Featured Stories

Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says

Three Device Areas Added to CDRH’s Device-Advancing TAP Program

Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand

Draft Guidance Covers Using URRAs in Combo Product Applications

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Three Healthcare Titans Make Deals to Expand Their Portfolios

To View This Article:

Login

Subscribe To FDAnews

Buy This Article Now

The Revised ICH E8: A Guide to New Clinical Trial Requirements